Moreover, our finding that BRAF mutants exhibited lower TERT expression compared with non-BRAF mutants in TERT promoter-mutated samples somewhat contradicts the proposed model of TERT reactivation in BRAF-mutated melanoma samples through acquisition of TERT promoter mutations, subsequent binding of TCF, and thus increased TERT expression [44]. The gene discussed is HNF4A; the disease is melanoma.